Proteome and phosphoproteome signatures of recurrence for HPV + head and neck squamous cell carcinoma

• Published in: Communications medicine Vol. 2; no. 1; p. 95
• Main Authors: Kaneko, Tomonori, Zeng, Peter Y F, Liu, Xuguang, Abdo, Rober, Barrett, John W, Zhang, Qi, Nichols, Anthony C, Li, Shawn Shun-Cheng
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group UK 30.07.2022; Nature Portfolio
• Subjects: Head and neck cancer; Proteomics
• ISSN: 2730-664X; 2730-664X
• DOI: 10.1038/s43856-022-00159-8

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and the human papillomavirus (HPV )-driven subtype is the fastest rising cancer in North America. Although most cases of HPV HNSCC respond favorably to the treatment via surgery followed by radiochemotherapy, up to 20% recur with a poor prognosis. The molecular and cellular mechanisms of recurrence are not fully understood. To gain insights into the mechanisms of recurrence and to inform patient stratification and personalized treatment, we compared the proteome and phosphoproteome of recurrent and non-recurrent tumors by quantitative mass spectrometry. We observe significant differences between the recurrent and non-recurrent tumors in cellular composition, function, and signaling. The recurrent tumors are characterized by a pro-fibrotic and immunosuppressive tumor microenvironment (TME) featuring markedly more abundant cancer-associated fibroblasts, extracellular matrix (ECM), neutrophils, and suppressive myeloid cells. Defective T cell function and increased epithelial-mesenchymal transition potential are also associated with recurrence. These cellular changes in the TME are accompanied by reprogramming of the kinome and the signaling networks that regulate the ECM, cytoskeletal reorganization, cell adhesion, neutrophil function, and coagulation. In addition to providing systems-level insights into the molecular basis of recurrence, our work identifies numerous mechanism-based, candidate biomarkers and therapeutic targets that may aid future endeavors to develop prognostic biomarkers and precision-targeted treatment for recurrent HPV HNSCC.